2023 World Conference on Lung Cancer (Posters)-P2.08. TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)

P2.08. TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

Back to course

Pdf Summary

The TROPION-Lung08 study is a phase 3 trial investigating the combination of datopotamab deruxtecan (Dato-DXd) and pembrolizumab in treatment-naive patients with advanced/metastatic non-small cell lung cancer (NSCLC). The study aims to evaluate the efficacy and safety of this combination compared to pembrolizumab alone.<br /><br />Dato-DXd is an antibody-drug conjugate composed of a humanized antibody that targets the trophoblast cell-surface antigen 2 (TROP2) linked to a topoisomerase I inhibitor payload via a cleavable linker. In previous trials, Dato-DXd has shown promising results as a monotherapy and in combination with pembrolizumab in patients with advanced NSCLC.<br /><br />The primary endpoints of the TROPION-Lung08 study are progression-free survival (PFS) and overall survival (OS) assessed by blinded independent central review. Secondary endpoints include objective response rate, duration of response, time to response, disease control rate, and patient-reported outcomes.<br /><br />The study population consists of patients with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations and with high PD-L1 expression. Patients must have an Eastern Cooperative Oncology Group performance status of 0 or 1 and have not received previous systemic therapy for advanced/metastatic NSCLC.<br /><br />Enrollment in the study is ongoing, and data from the trial will provide valuable information about the efficacy and safety of the combination of Dato-DXd and pembrolizumab as a first-line treatment option for patients with advanced NSCLC. The study is sponsored by Daiichi Sankyo, Inc., and Pembrolizumab is being provided under agreement by Merck Sharp & Dohme Corp.<br /><br />Results from the TROPION-Lung08 study will contribute to the growing understanding of the treatment landscape for patients with advanced NSCLC and may have implications for improving outcomes and survival in this patient population.

Asset Subtitle

Caicun Zhou

Meta Tag

Speaker Caicun Zhou

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

TROPION-Lung08 study

datopotamab deruxtecan

Dato-DXd

pembrolizumab

non-small cell lung cancer

NSCLC

antibody-drug conjugate

progression-free survival

overall survival

PD-L1 expression